- Home
- SRTS vs ANVS Comparison
SRTS vs ANVS Comparison
Compare SRTS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | ANVS |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 42.6M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRTS | ANVS |
|---|---|---|
| Price | $2.83 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.38 | ★ $10.50 |
| AVG Volume (30 Days) | 15.8K | ★ 626.4K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $41.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $0.93 |
| 52 Week High | $5.49 | $5.50 |
Technical Indicators
Market Signals| Indicator | SRTS | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.48 | 39.25 |
| Support Level | $2.75 | N/A |
| Resistance Level | $3.17 | $1.43 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 27.78 | 30.48 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.